GLP-1 Weight Loss Injections

Medically prescribed GLP-1 receptor agonist injection pens including Liraglutide, Semaglutide, and Tirzepatide for clinically proven weight loss. Administered under doctor supervision with tailored dosing and regular follow-up monitoring.

GLP-1 (glucagon-like peptide-1) receptor agonist medications represent the most significant advance in medical weight management in a generation. Halley Body Slimming Clinic offers three classes of these injectables, all prescribed and supervised by a licensed physician. Liraglutide — the original GLP-1 agonist marketed as Victoza and Saxenda — mimics a naturally occurring gut hormone that regulates appetite and blood sugar. Injected daily, it suppresses appetite, slows gastric emptying, and promotes satiety. Clinical trials demonstrated average weight loss of 5–8% of body weight over 56 weeks compared to placebo. Semaglutide represents the next generation — a once-weekly GLP-1 agonist that achieves greater receptor binding duration. Sold globally as Ozempic (diabetes indication) and Wegovy (weight management), semaglutide trials have demonstrated average weight loss of 15% of body weight, making it substantially more effective than Liraglutide for most patients. The clinic offers semaglutide at SGD 1,250 per injection pen. Tirzepatide is the newest and most potent option — a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist marketed as Mounjaro and Zepbound. By targeting two incretin pathways simultaneously, Tirzepatide achieved average weight loss of 20–22% of body weight in the SURMOUNT trials, outperforming all prior weight loss medications. The clinic stocks both 10mg (SGD 1,250/pen) and 15mg (SGD 1,480/pen) doses. All GLP-1 programmes at Halley Body Slimming Clinic include an initial clinical consultation to assess suitability, contraindications, and appropriate starting dose, followed by a structured titration protocol to minimise gastrointestinal side effects. Follow-up appointments monitor weight loss progress, metabolic markers, and dose optimisation throughout the treatment period.